Bi-directional sequencing of exons 2, 3, and 4 of the KRAS (includes G12C mutation) gene including codons 12, 13, 59, 61, 117, and 146. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12 and 13.
This test is only available through the Amgen-sponsored Biomarker AssistTM KRAS G12C Single Gene Test Program for patients with stage IV non-small cell lung carcinoma (NSCLC). A separate test request form is required. Please visit the Test Program webpage for more information and to download the KRAS G12C Single Gene Test Request Form.
To order additional testing outside the KRAS G12C Single Gene Test Program on the same specimen, please send the tissue block rather than cut slides and submit the NeoGenomics Test Request concurrently with the KRAS Test Request Form.
The KRAS G12C mutation is the most prevalent oncogenic driver in NSCLC, detected in approximately 13% of patients. Tumors with the KRAS G12C mutation may respond to targeted therapy such as sotorasib.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
7 days
- Pakkala S, et al. JCI Insight. 2018;3 e120858.
- Nassar AH, Adib E, Kwiatkowski DJ. N Engl J Med. 2021;384:185-187. doi: 10.1056/NEJMc2030638.